GlassScriptPhysician profile
Amir Agha
NPI 1730144114
$42,176.15
in general payments reported to CMS, 2019-2025
33 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $5,423 · 2021: $4,085 · 2022: $1,603 · 2023: $1,607 · 2024: $1,532 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,231.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19,062.79 | 2019-2024 | Orencia |
| Amgen INC. | $10,170.78 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $4,368.42 | 2019-2025 | |
| Janssen Biotech, INC. | $2,031.02 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,599.46 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $669.22 | 2019-2025 | |
| Abbvie INC. | $664.19 | 2019-2025 | Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $385.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $309.13 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $301.57 | 2020-2024 | Acthar |
| Lilly USA, LLC | $272.48 | 2021-2022 | |
| Horizon Therapeutics Plc | $265.38 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $256.07 | 2019-2022 | |
| Organon LLC | $234.33 | 2023-2025 | Hadlima, Renflexis |
| Glaxosmithkline, LLC. | $204.59 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $183.98 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $174.80 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $164.88 | 2022-2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.61 | 2019-2024 | Ofev |
| Bioventus LLC | $96.00 | 2021-2025 | Supartz Fx Sodium Hyaluronate |
| Mallinckrodt Enterprises LLC | $87.28 | 2019 | |
| Alexion Pharmaceuticals, INC. | $86.24 | 2019-2023 | Strensiq |
| Antares Pharma, INC. | $83.66 | 2019-2021 | |
| Genentech USA, INC. | $81.53 | 2019-2024 | Actemra |
| Radius Health, INC. | $66.44 | 2021-2025 | Tymlos |
| US Oncology Corporate, INC. | $53.61 | 2024 | |
| Medtronic, INC. | $36.11 | 2024-2025 | Intellis Adaptivestim |
| Arbor Pharmaceuticals, INC. | $29.88 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $26.74 | 2019 | |
| Medexus Pharma, INC. | $24.22 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.64 | 2024 | |
| Boston Scientific Corporation | $17.54 | 2021 | |
| Genzyme Corporation | $16.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Agha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.